×
About 1,503 results

ALLMedicine™ Ataxia Telangiectasia Center

Research & Reviews  592 results

Brain distribution of berzosertib: an ATR inhibitor for the treatment of glioblastoma.
https://doi.org/10.1124/jpet.121.000845
The Journal of Pharmacology and Experimental Therapeutics; Talele S, Zhang W et. al.

Sep 25th, 2021 - The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Glioblastoma (GBM) is an aggressive and infiltrative primary brain tumor with an extremely ...

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with A...
https://doi.org/10.1136/ijgc-2021-002973
International Journal of Gynecological Cancer : Official ... Banerjee S, Stewart J et. al.

Sep 15th, 2021 - ARID1A (AT-rich interactive domain containing protein 1A) loss-of-function mutations have been reported in gynecological cancers, including rarer subtypes such as clear cell carcinoma. Preclinical studies indicate that ARID1A mutant cancers displa...

Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telang...
https://doi.org/10.1002/mds.28788
Movement Disorders : Official Journal of the Movement Dis... Veenhuis SJG, van Os NJH et. al.

Sep 14th, 2021 - Treatment of animal models with ataxia telangiectasia (A-T) with nicotinamide riboside (NR) improved their neurological outcome and survival. The aim of this study is to investigate the effects of NR in patients with A-T. In this open-label, proof...

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391778
JAMA Oncology; Pal SK, Frankel PH et. al.

Aug 27th, 2021 - Preclinical studies suggest that inhibition of single-stranded DNA repair by ataxia telangiectasia and Rad3 (ATR) may enhance the cytotoxicity of cisplatin, gemcitabine, and other chemotherapeutic agents. Cisplatin with gemcitabine remains the sta...

Cellular functions of the protein kinase ATM and their relevance to human disease.
https://doi.org/10.1038/s41580-021-00394-2 10.1186/s13023-016-0543-7 10.1038/nrm3546 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O 10.1016/j.dnarep.2009.04.006 10.1146/annurev-biochem-060614-034335 10.1038/nature08467 10.1126/science.1140321 10.1126/scisignal.2001034 10.15252/embj.2020104400 10.1038/nrm2514 10.1126/scisignal.aaq0702 10.1126/scisignal.aan5598 10.1126/science.1192912 10.1016/j.devcel.2018.07.011 10.1038/emboj.2010.330 10.1016/j.dnarep.2013.11.002 10.1038/mt.2012.203 10.1038/nature14512 10.1128/MCB.01125-06 10.3324/haematol.2019.234385 10.1016/j.str.2019.10.012 10.1126/sciadv.1700933 10.1016/j.str.2019.10.013 10.1038/ncomms11655 10.1080/15384101.2016.1158362 10.1126/science.1108297 10.1093/emboj/cdg541 10.1016/j.molcel.2016.11.004 10.1073/pnas.0504211102 10.1128/MCB.01382-07 10.1038/nature01368 10.1074/jbc.M110.204065 10.1038/sj.emboj.7601231 10.1134/S0006297916130058 10.1073/pnas.1416031112 10.1074/jbc.M109.030601 10.1038/embor.2009.97 10.4161/cc.9.2.10506 10.1093/nar/gkv1196 10.1016/j.molcel.2011.09.016 10.1016/j.isci.2020.101972 10.1083/jcb.201806197 10.1038/s41422-019-0176-1 10.1038/nature25023 10.1016/j.cell.2017.01.002 10.1101/gad.301325.117 10.1089/ars.2013.5668 10.1002/em.22087 10.1158/0008-5472.CAN-03-3207 10.1002/jcp.20141 10.1016/j.celrep.2015.10.024 10.1074/jbc.C100466200 10.4161/nucl.11176 10.1073/pnas.0802885105 10.1083/jcb.200708210 10.1083/jcb.200709008 10.1016/j.dnarep.2020.102950 10.1016/j.molcel.2017.05.015 10.3109/10409238.2016.1172552 10.1101/cshperspect.a012716 10.1038/35043058 10.1101/cshperspect.a016410 10.1038/nature06337 10.1016/j.molcel.2009.12.002 10.1371/journal.pgen.1003277 10.1016/j.molcel.2012.11.020 10.1093/nar/gkp1164 10.1038/sj.onc.1204003 10.1126/science.286.5442.1162 10.15252/embr.201541455 10.1093/nar/gkv754 10.1016/j.dnarep.2009.07.006 10.1093/abbs/gmx055 10.1038/sj.emboj.7600469 10.3389/fgene.2013.00099 10.4161/cc.27946 10.1038/embor.2012.58 10.1038/nsmb.2212 10.1038/ncomms4561 10.1038/nature07215 10.1074/jbc.M808906200 10.1038/nrm.2017.48 10.1093/nar/gky088 10.1083/jcb.201303073 10.1016/j.pbiomolbio.2014.12.003 10.1074/jbc.M611605200 10.1016/j.molcel.2004.10.029 10.1038/sj.emboj.7601255 10.2183/pjab.90.365 10.1016/j.dnarep.2008.06.015 10.1016/j.dnarep.2017.01.004 10.1101/gad.333237.119 10.1016/j.molcel.2011.03.019 10.1016/j.molcel.2013.01.002 10.1074/jbc.M113.457440 10.1126/science.1231573 10.1126/science.1230624 10.1016/j.cell.2013.05.023 10.1016/j.cell.2010.03.012 10.1038/s41467-018-07729-2 10.1016/j.molcel.2020.12.025 10.1093/nar/gkaa723 10.1007/s42764-020-00017-8 10.1016/j.tcb.2015.07.009 10.1126/sciadv.aay0922 10.1038/s41598-019-42901-8 10.1259/bjr.20130685 10.1038/nrc1977 10.1021/cb300648v 10.1371/journal.pone.0058239 10.1038/nn.3715 10.1038/emboj.2009.302 10.4161/cc.9.3.10598 10.7554/eLife.14709 10.1083/jcb.201204098 10.1083/jcb.201204035 10.1016/j.chembiol.2010.04.012 10.1016/j.dnarep.2014.03.020 10.1038/ncomms4347 10.1038/s41467-020-14638-w 10.1111/cas.12067 10.1016/j.molcel.2016.10.011 10.1093/emboj/18.23.6619 10.1242/bio.20121834 10.1083/jcb.201504005 10.1042/BST0340523 10.1038/ncomms12889 10.1016/j.molcel.2021.01.019 10.1038/emboj.2008.229 10.1016/j.mad.2016.07.009 10.1038/nature20790 10.1016/B978-0-444-64189-2.00007-X 10.1016/j.cell.2009.03.010 10.1074/jbc.M401049200 10.1038/srep43897 10.1038/s41580-019-0206-3 10.1371/journal.pone.0090219 10.1016/j.cell.2017.07.043 10.1093/nar/gkz025 10.1016/j.molcel.2014.10.020 10.1016/j.cell.2018.08.056 10.1016/j.celrep.2019.08.041 10.7554/eLife.42733 10.1128/MCB.01195-12 10.3390/molecules24081583 10.3389/fnmol.2018.00216 10.1155/2012/428010 10.1155/2019/2105607 10.1016/S1568-7864(01)00007-6 10.1002/ana.1005 10.1155/2017/6745840 10.1038/labinvest.3700354 10.1016/S0014-5793(00)01422-8 10.1179/135100003125001206 10.1089/15230860260196254 10.1046/j.1365-2249.1999.01000.x 10.1016/j.dnarep.2011.05.004 10.1164/rccm.201611-2210LE 10.1016/j.mrgentox.2018.05.009 10.1371/journal.pone.0244060 10.1074/jbc.M808116200 10.1002/ajmg.1320420524 10.1086/301755 10.1002/(SICI)1096-8628(19980113)75:2<141::AID-AJMG4>3.0.CO;2-W 10.1073/pnas.96.17.9915 10.1073/pnas.94.23.12688 10.1016/S0092-8674(00)80086-0 10.1101/gad.10.19.2411 10.1093/hmg/ddh189 10.1016/j.dnarep.2006.05.003 10.1038/nature02989 10.1002/stem.125 10.1074/jbc.274.48.34277 10.1038/ncb3230 10.1073/pnas.95.17.10146 10.1182/blood-2011-08-373639 10.1038/sj.onc.1201037 10.1038/s41598-019-41108-1 10.1016/j.cub.2009.10.039 10.1073/pnas.97.2.871 10.1016/S0304-3940(98)00576-X 10.1016/S0006-8993(99)01813-2 10.1152/jn.00006.2016 10.1126/scisignal.2001712 10.1126/science.1121513 10.1016/j.molcel.2010.09.008 10.1038/cr.2010.179 10.1158/0008-5472.CAN-18-2063 10.1093/nar/gku529 10.1016/j.redox.2020.101674 10.1016/j.neulet.2017.06.052 10.1016/j.bbadis.2009.08.013 10.1007/978-3-319-71779-1_3 10.1016/j.redox.2020.101511 10.1172/JCI31604 10.1093/hmg/ddm166 10.1016/j.cmet.2016.09.004 10.1038/s41467-018-03948-9 10.1073/pnas.1820245116 10.1073/pnas.0803520105 10.1007/s11010-020-03917-1 10.15252/embr.202050500 10.1073/pnas.1722452115 10.1080/15548627.2018.1475818 10.1074/jbc.M607704200 10.1242/jcs.223008 10.1016/j.cmet.2013.04.003 10.18632/aging.100016 10.1038/s41419-018-0416-1 10.1016/j.redox.2020.101762 10.18632/oncotarget.10744 10.1186/s13024-016-0127-y 10.1038/s41419-019-1475-7 10.1128/MCB.01301-08 10.1101/sqb.2000.65.127 10.1158/0008-5472.CAN-04-0442 10.1073/pnas.1418139112 10.1016/S0079-6603(06)81005-6 10.4049/jimmunol.178.1.103 10.1038/nrm.2017.53 10.1101/gad.291518.116 10.1093/nar/gkx565 10.1093/nar/gkg761 10.1093/nar/gkm933 10.1016/j.molcel.2017.01.003 10.1016/j.molcel.2016.03.008 10.1038/s41586-020-2013-6 10.1016/j.celrep.2018.07.083 10.1038/s41467-017-02253-1 10.1038/nature10404 10.1371/journal.pone.0049301 10.1016/j.molcel.2021.05.009 10.1073/pnas.0406182101 10.1073/pnas.2237114100 10.1016/j.dnarep.2005.05.011 10.1523/JNEUROSCI.5552-09.2010 10.2741/3297 10.1073/pnas.0606526103 10.1016/j.mad.2015.04.001 10.1007/s11064-012-0895-x 10.5483/BMBRep.2014.47.8.119 10.1126/science.aat8407 10.1101/2020.04.08.032250 10.1016/j.tcb.2020.02.002 10.1074/jbc.M113.497974 10.1038/ncomms9088 10.1016/j.celrep.2019.04.031 10.1016/j.cell.2015.07.047 10.1073/pnas.1713912115 10.1038/s41422-019-0141-z 10.1038/nrm.2017.7 10.1101/gad.334433.119 10.15252/embr.201949585 10.4161/pri.5.3.17230 10.1146/annurev-biochem-060614-034325 10.1016/j.tibs.2014.01.003 10.1016/S0092-8674(02)01247-3 10.1038/nature03314 10.3390/ijms20163896 10.1093/nar/gkx635 10.1371/journal.pone.0016422 10.1042/BJ20081135 10.1523/JNEUROSCI.0172-14.2014 10.1091/mbc.E17-12-0735 10.15252/embj.201696394 10.1101/gad.2021311 10.2174/138920291501140306113344 10.1186/s40035-017-0077-5 10.1016/j.freeradbiomed.2012.09.016 10.1038/s41467-017-02299-1 10.1038/nn.3514 10.1038/nn.4604 10.1515/revneuro-2016-0035 10.1074/jbc.M111.276550 10.1128/MCB.21.5.1828-1832.2001 10.1126/scitranslmed.aaf9246 10.1002/dvdy.24522 10.1182/blood-2012-09-456897 10.1016/j.arr.2016.05.002 10.1038/s41572-019-0074-3 10.1016/S0896-6273(00)80943-5 10.1093/hmg/7.5.913 10.1083/jcb.201105092 10.1007/s00415-018-9076-4 10.1007/s00401-019-02004-0 10.1016/j.neuint.2016.01.007 10.2174/1570159X15666170529104000 10.1007/s12311-010-0182-9 10.1523/JNEUROSCI.3909-08.2008 10.1086/373883 10.1002/iub.2457 10.3389/fncel.2018.00264 10.1093/nar/gkaa140 10.1038/cddiscovery.2017.76 10.1016/S0014-5793(99)00664-X 10.1038/sj.onc.1206167 10.1074/jbc.272.14.9489 10.1016/S1388-1981(99)00022-0 10.1111/j.1365-3083.1993.tb01692.x 10.1016/S0306-4522(99)00581-3 10.1101/cshperspect.a028035 10.1073/pnas.1906124116 10.3233/JPD-130230 10.3233/JHD-160205 10.1016/j.tibs.2012.03.003 10.1038/s41593-018-0235-9 10.1002/prot.24285 10.1242/dmm.030205 10.1016/j.dnarep.2013.04.014 10.1093/hmg/ddv356 10.1371/journal.pone.0190821 10.1189/jlb.4VMA0716-316R 10.1073/pnas.95.21.12653 10.3389/fnins.2011.00046 10.1073/pnas.1718582115 10.3389/fphar.2012.00157 10.1016/j.freeradbiomed.2004.01.003 10.1016/j.freeradbiomed.2006.06.018 10.1038/nn.3564 10.1016/j.neuron.2011.05.003 10.3390/molecules25082000 10.1016/j.stem.2016.07.017 10.1098/rsob.180177 10.1371/journal.pgen.1004318 10.1093/nar/gky099 10.1016/j.celrep.2016.06.075
Nature Reviews. Molecular Cell Biology; Lee JH, Paull TT

Aug 26th, 2021 - The protein kinase ataxia telangiectasia mutated (ATM) is a master regulator of double-strand DNA break (DSB) signalling and stress responses. For three decades, ATM has been investigated extensively to elucidate its roles in the DNA damage respon...

see more →

Drugs  1 results see all →

News  7 results

Drug Duo Targeting ATR Enzyme Shrinks Small Cell Lung Cancer Tumors
https://www.medscape.com/viewarticle/949638

Apr 21st, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...

Irinotecan shows promise for triple-negative breast cancer
https://www.mdedge.com/hematology-oncology/article/217772/breast-cancer/irinotecan-shows-promise-triple-negative-breast?channel=39313
Caleb Rans

Feb 24th, 2020 - The topoisomerase I (TOP1) inhibitor irinotecan could be effective in treating triple-negative breast cancer (TNBC), according to results from a preclinical study published in Science Translational Medicine. Florence Coussy, MD, PhD, of Institut C.

Pancreatic Ductal Carcinoma: Slow Progress for a Hard-to-Treat Cancer
https://www.onclive.com/publications/oncology-live/2018/vol-19-no-2/pancreatic-ductal-carcinoma-slow-progress-for-a-hardtotreat-cancer

Jan 17th, 2018 - Johanna C. Bendell, MD The incidence of pancreas cancer continues to rise in many countries.1 In 2017, an estimated 53,600 cases were diagnosed in the United States, representing an approximately 45% increase over the past decade.2,3 Pancreatic du...

AT Children’s Project Advisors Elected to National Academy of Sciences
https://www.mdedge.com/neurology/article/116228/rare-diseases/childrens-project-advisors-elected-national-academy-sciences

Oct 1st, 2016 - Longtime scientific advisors to the AT (Ataxia Telangiectasia) Children’s Project Nathaniel Heintz, PhD, and Michael Kastan, MD, PhD, have been elected to the National Academy of Sciences.

Olaparib + paclitaxel for metastatic gastric cancer
https://www.mdedge.com/hematology-oncology/article/101954/gastroenterology/olaparib-paclitaxel-metastatic-gastric-cancer
Mary Ann Moon

Aug 17th, 2015 - Adding olaparib to second-line paclitaxel therapy for recurrent or metastatic gastric adenocarcinoma improved overall survival but not progression-free survival in a phase II clinical trial, investigators reported online Aug. 17 in Journal of Clin.

see more →

Patient Education  1 results see all →